Stanley Center at the Broad Institute and New York Stem Cell Foundation Partner to Develop Stem Cell Resource for Schizophrenia and Psychiatric Diseases The New York Stem Cell Foundation and the Stanley Center at the Broad Institute of MIT and Harvard are partnering to create a foundational stem cell resource to study psychiatric disorders through the production of induced pluripotent stem cell lines from individuals with schizophrenia and other psychiatric disorders. [The Broad Institute] Press Release Frederick Alt of Harvard University and Boston Children’s Hospital Awarded 2015 Szent-Gyorgyi Prize for Progress in Cancer Research The National Foundation for Cancer Research announced that Frederick Alt, Ph.D., Professor of Genetics at Harvard Medical School, Director of the Program in Cellular and Molecular Medicine at Boston Children’s Hospital, and Howard Hughes Medical Institute Investigator has been awarded the 2015 Szent-Györgyi Prize for Progress in Cancer Research. [National Foundation for Cancer Research] Press Release Dr. Julie Brahmer, MD, Named March LUNGevity Hero for Research in Groundbreaking Field of Immunotherapy To kick off Women in History month, LUNGevity Foundation announced Dr. Julie Brahmer, MD, as the March LUNGevity Hero for her work in the field of immunotherapy for lung cancer patients. [LUNGevity Foundation (PR Newswire Association LLC)] Press Release | Blog Post Ocata Therapeutics Receives Two New Patents for Immune-Modulatory Cell Technology Ocata Therapeutics, Inc. announced that the United States Patent and Trademark Office issued two U.S. patents directed to the company’s hemangio-derived mesenchymal cells (HMCs). Ocata’s HMC technology introduces a new era of cell therapy for ophthalmic, autoimmune and inflammatory diseases. This development enables the generation of a potentially unlimited supply of potent HMCs from renewable pluripotent stem cell sources. [Ocata Therapeutics, Inc.] Press Release Rowan Researcher Targets Stem Cell-Based Therapy for Rare Childhood Disease Paola Leone, PhD, the director of the Cell and Gene Therapy Center and a professor of Cell Biology at the Rowan University School of Osteopathic Medicine, has been awarded a three-year, $477,000 grant from the National Institute of Neurological Disorders and Stroke to develop a stem cell-based therapy for Canavan disease, a rare but devastating neurological disorder in children that typically takes a child’s life by age 10. [Rowan University] Press Release T-Cell Therapy Clinical Trial Now Offered to Cancer Patients at C.S. Mott Children’s Hospital A clinical trial using T-cell therapy that uses the patients’ own immune cells to hunt down cancer cells is now being offered at the University of Michigan’s C.S. Mott Children’s Hospital. “For patients for whom we’ve exhausted all other options, this therapy has provided hope against a highly aggressive form of ALL, in situations where nothing else has been successful,” says John Levine, M.D., clinical director of the Pediatric Blood and Marrow Transplantation Program at C.S. Mott Children’s Hospital. [University of Michigan] Press Release Aduro Biotech Collaborates with Leaders in Cancer Research on Investigator-Sponsored Phase II Trial Combining Aduro’s Innovative Immunotherapies with Anti-PD-1 Technology to Treat Patients with Advanced Pancreatic Cancer Aduro Biotech, Inc. announced the initiation of an investigator-sponsored Phase II clinical trial of the company’s immuno-oncology product candidates GVAX Pancreas and CRS-207 in combination with Bristol-Myers Squibb’s Opdivo, a monoclonal antibody against programmed death-1 receptor. [Aduro Biotech, Inc.] Press Release Arrowhead Begins Phase I Trial of ARC-AAT for Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency Arrowhead Research Corporation announced that it has initiated dosing in a Phase I clinical trial of ARC-AAT, the company’s candidate for the treatment of liver disease associated with alpha-1 antitrypsin deficiency, a rare genetic disorder that severely damages the liver and lungs of affected individuals. [Arrowhead Research Corporation] Press Release U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Yervoy® (Ipilimumab) as Adjuvant Treatment for Patients with Stage 3 Melanoma Who Are at High Risk of Recurrence Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has accepted for filing and review the supplemental biologics license application for Yervoy for the adjuvant treatment of patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection. [Bristol-Myers Squibb Company] Press Release Celimmune Founded to Develop Novel Therapeutics for Celiac and Other Serious Autoimmune Diseases Celimmune LLC announced that it will initially focus its distinctive core competence in translational medicine, immunotherapy clinical development and commercialization on combating celiac disease. [Celimmune LLC (PR Newswire Association LLC)] Press Release ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy against Chronic Hepatitis B ABIVAX announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [ABIVAX] Press Release |